Bleeding Disorders Treatment Market

Bleeding Disorders Treatment Market Outlook (2021-2027)

The global bleeding disorders treatment market reached a valuation of US$ 12.7 Billion in 2020, and this industry is expected to rise at a high CAGR of 6.7% to reach US$ 19.9 Billion by the end of 2027.

The hemophilia A disease segment is projected to increase at 6.6% CAGR from 2021 to 2027. Rising awareness about the effectiveness of hemophilia A medicines is driving the complementing market growth.

Report Attributes	Details
Market Size (2020)	US$ 12.7 Billion
Projected Year Value (2027)	US$ 19.9 Billion
Global Market Growth Rate (2021-2027)	6.7% CAGR
China Market Growth Rate (2021-2027)	10.1%
Key Companies Profiled	Bayer AG CSL Behring Grifols International SA Novo Nordisk A/S Octapharma AG Pfizer, Inc.

Revenue Analysis of Bleeding Disorders Treatment from 2017-2020 Vs Market Outlook for 2021-2027

“Growing Awareness of Bleeding Disorders across the World”

As per Fact.MR, a market research and competitive intelligence provider, the global market for bleeding disorders treatment was valued at US$ 12.7 Bn in 2020.

A bleeding disorder is a medical illness in which blood coagulation is disrupted, preventing a blood clot from forming. Internal and exterior bleeding diseases are both possible. When a person sustains an injury, blood pours out of the body. Internal bleeding occurs when blood continues to flow beneath the skin, similar to a clot in the brain.

In hemophilic individuals or people with other bleeding disorders, a bleeding disease impairs the process of blood coagulation by blocking the formation of blood clots. The majority of these bleeding problems are hereditary, although others can be acquired as a result of liver disease, pharmaceutical side effects, low red blood cell count, vitamin K insufficiency, and other factors.

A major driver for the expansion of the global bleeding disorders treatment market is high investments in R&D activities pertaining to the creation of recombinant factors, along with advances in the technology utilized to treat bleeding disorders among patients.

Considering these factors, the market is projected to witness high growth over the forecast period, registering a CAGR of 6.7% to reach US$ 19.9 Billion by 2027.

Which Factors Can Positively Influence Demand for Bleeding Disorders Treatment Medications?

“Growing Prevalence of Bleeding Disorders and Advancements in Treatments to Bolster Market Revenue”

The market for bleeding disorders treatment is being driven by an increase in the number of people with bleeding disorders. More than 1,125,000 males worldwide have a genetic bleeding problem, with 418,000 having a mild form of the disease that is typically undetected. Because a huge number of patients are being treated in some way, the market for bleeding disorders treatment has been rising.

Many corporations and scientific institutes have been working to develop new drugs and improve existing ones in order to boost patient awareness of therapy and adoption rates.

Many replacement medications now have easier delivery methods, lower immunogenicity, higher potency, and longer half-lives. For the past five years, bioengineering advancements have aided in the treatment of bleeding diseases. The bleeding disorders treatment market is expected to rise as a result of these developments over the coming years.

What Restraints are Being Faced by Bleeding Disorders Treatment Providers?

“Shortage of Clinicians & Unfavorable Reimbursement Situation Hampering Market Growth”

The high cost of treatment is a major roadblock in the bleeding disorders treatment market. Daily outpatient appointments, hospitalization, and lab testing all have prohibitively high prices. Other issues, such as a lack of knowledge in some developing nations, are projected to stymie the expansion of the market for acquired bleeding disorders treatments.

The dearth of skilled specialists and trained expertise would pose a significant barrier to the expansion of the bleeding disorders treatment market. The market's growth pace will be slowed by a lack of access to adequate treatment due to high prescription costs. The scope of growth will also be limited by a lack of favorable reimbursement policies.

Which Region is Expected to Lead the Global Bleeding Disorders Treatment Market?

“Accessibility to Healthcare Facilities to Propel Industry Expansion in North America”

North America is expected to lead the worldwide bleeding disorders treatment market because of its affordability and accessibility to healthcare facilities. The expansion of the market is aided by patient awareness of bleeding disorders, as well as government and private-sector treatment programs.

The market in the region is the quick continued development of enterprises working in the drug industry due to the early stage acceptance of established medical technologies. Because of the rising prevalence of various blood diseases and increased awareness among the patient population in this area, North America is likely to hold a significant market share in the blood disorders therapeutics market.

Country-wise Insights

Will the U.S. Bleeding Disorders Treatment Market Exhibit Steady Growth?

“Favorable Reimbursement & Insurance Policies Boosting Market Value”

The U.S. bleeding disorders treatment market was valued at US$ 3.4 Bn in 2020 and is expected to rise at a significant CAGR over the forecast period. According to the World Federation of Hemophilia, over 18 thousand persons in the United States have hemophilia and over 11 thousand people have Von Willebrand Disease (VWD). Hemophilia A affects 1 in every 5,000 male births, and about 400 kids are born with the disease each year.

Expansion of the bleeding disorders treatment market in the United States is aided by factors such as high rates of bleeding disorders along with favorable reimbursement and insurance policies.

Moreover, rising investments in research & development to create treatment options for blood disorders, as well as the availability of well-established healthcare infrastructure, are driving the market expansion.

Why is Demand for Bleeding Disorders Treatment Systems Surging in China?

“Rapid Availability of Drugs & Treatments Driving China Market Growth”

China, the world's second-largest economy, is expected to reach a projected market size of US$ 4.3 Bn by 2027, representing a 10.1% CAGR from 2021 to 2027. The market in China is likely to have a big revenue share in the bleeding disorders treatment market because people are becoming more aware of hereditary diseases.

Rising occurrence of bleeding disorders among patients and the availability of drugs or treatments to address these illnesses are driving market growth. The market In China is likely to benefit from factors such as increased R&D efforts and pharmaceutical companies' increased focus on creating novel drugs.

Category-wise Insights

Which Bleeding Disorders Treatment Type is Expected to Showcase Highest Growth?

“Rising R&D Expenditure on Hemophilia A Drugs & Treatments Driving Market Growth”

The hemophilia A disease segment is expected to rise at a 6.6% CAGR and reach US$ 11.1 Bn over the forecast period. The bleeding disorders treatment market is divided into hemophilia A, hemophilia B, and other forms based on type. The increased number of patients with hemophilia A and rising R&D expenditure on hemophilia medicines are driving market expansion.

The hemophilia A segment dominated the bleeding disorder treatment market in the past, and this trend is expected to continue over the forecast period. This is due to an increase in the prevalence of bleeding disorders, as well as an increase in the availability of hemophilia treatment and medications in the global hemophilia treatment market.

Which Drug Class is Expected to Gain Momentum?

“Recombinant Coagulation Factor Concentrates Gaining Traction Due to Increasing Need to Treat Blood-related Disorders”

The recombinant coagulation factor concentrates segment is predicted to increase at the fastest rate in the market. This increase can be ascribed to increased R&D activities and pharmaceutical companies' increased attention to recombinant goods, which has resulted in the launch of new medications.

Primary drivers of the segment are the rising prevalence of blood diseases and the increasing acceptance of recombinant coagulation factor concentrates. In the treatment of illnesses such as hemophilia, recombinant coagulation factor concentrates are employed (prevention and control of hemorrhagic episodes).

COVID-19 Impact on Demand for Bleeding Disorders Treatment Devices

The COVID-19 pandemic hampered the bleeding disorders treatment market. Many clinical trials for the treatment of blood diseases were impacted by the COVID-19 pandemic. In addition, hospitals cancelled hemophilia replacement procedures. Aside from that, the supply chain for bleeding disorders treatments and products was affected due to the travel ban and lockdown.

The bleeding disorders treatment market is fueled by a huge consumer base, increased knowledge of bleeding disorders and available treatments, and advantageous remuneration policies. Existing brand patents will expire, allowing generic medicine producers to access the bleeding disorder therapeutics market. Increased government initiatives and the implementation of various awareness programs are expected to support the bleeding disorders treatment market over the coming years.

Competitive Landscape

The blood disorders treatment market is competitive and fragmented, with a number of prominent companies operating in this space. In terms of market share, the industry is currently dominated by a few significant competitors.

For instance,

• In November 2020, Pfizer announced the start of the Phase III BASIS study of marstacimab, an experimental treatment for treating persons with severe hemophilia A or B. The U.S. Food and Drug Administration (FDA) granted it fast track status for use in combination with inhibitors as a potential treatment for hemophilia A and B.

Key Segments of Bleeding Disorders Treatment Industry Research

• by Type :

  • Hemophilia A
  • Hemophilia B
  • Other Types

• by Drug Class :

  • Plasma-derived Coagulation Factor Concentrates
  • Recombinant Coagulation Factor Concentrates
  • Fibrin Sealants
  • Other Drug Classes

• by Region :

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA